Phase 2 – Talk Bio

Sanofi’s efdoralprin alfa (INBRX-101) achieves all endpoints in Phase 2 alpha-1 antitrypsin deficiency (AATD) trial

2 weeks ago talkbio0Tagged Acquisition, alpha 1-Antitrypsin Deficiency, efdoralprin alfa, INBRX-101, Inhibrx, Phase 2, plasma-derived therapy, Rare Diseases, sanofi, Zemaira

Sanofi; efdoralprin alfa; INBRX-101; AATD; alpha-1 antitrypsin deficiency; Phase 2; Inhibrx; acquisition; rare disease; plasma-derived therapy; Zemaira

Ono’s BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial

4 weeks ago talkbio0Tagged Advanced phase, Bristol Myers Squibb, EP4 antagonist, EP4 Antagonist ONO-4578, Episodic, HER2-negative, Malignant neoplasm of stomach, nivolumab, Opdivo, Pharmacotherapy, Phase 2, Progression-Free Survival

ONO-4578; EP4 antagonist; gastric cancer; Opdivo; nivolumab; Bristol-Myers Squibb; phase 2; progression-free survival; chemotherapy; HER2-negative; advanced; recurrent

OSE Immunotherapeutics Reports 65% Overall Survival Rate in Phase 2 Cancer Vaccine Trial at ASCO 2025

5 months ago talkbio0Tagged ASCO, neo-epitope cancer vaccine, OSE Immunotherapeutics, Pancreatic carcinoma, Phase 2, survival rate, Tedopi

OSE Immunotherapeutics; Tedopi; ASCO 2025; pancreatic cancer; neo-epitope cancer vaccine; phase 2; overall survival rate

Merus Phase 2 Data: Analysts See Strong Survival in Head & Neck Cancer, ‘Home Run’ Hopes Emerge

6 months ago talkbio0Tagged Cancer of Neck, Clinical Trials, Head, Keytruda, Merus, Overall Survival, pembrolizumab, Petosemtamab, Phase 2, Reaction, scenario

Merus; petosemtamab; Phase 2; overall survival; head and neck cancer; Pembrolizumab; Keytruda; clinical trial; analyst reaction; home run scenario

Xilio Therapeutics Stock Plunges Following Initial Phase 2 Data for Vilastobart in Colorectal Cancer Treatment

10 months ago talkbio0Tagged Colorectal Carcinoma, Phase 2, stock price, Vilastobart, Xilio

Xilio Therapeutics, Vilastobart, Anti-CTLA-4, Colorectal Cancer, Stock Price, Phase 2 Data

Cardiff Oncology’s Onvansertib Shows Promising Results in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial

11 months ago talkbio0Tagged Cardiff Oncology, first-line, onvansertib, ORR, Phase 2, RAS, RAS-mutated

Cardiff Oncology, Onvansertib, RAS-mutated metastatic colorectal cancer, Phase 2 CRDF-004 trial, objective response rate (ORR), first-line treatment.

Protara’s TARA-002 Cell Therapy Shows Exceptional Promise in Treating Non-Muscle Invasive Bladder Cancer

11 months ago talkbio0Tagged BCG-Naïve, BCG-Unresponsive, Carcinoma of urinary bladder, invasive, Cell Therapy, Clinical Trials, Lyophilized Inactivated Group A Streptococcus TARA-002, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Phase 2, Protara Therapeutics

Protara Therapeutics, TARA-002, Non-Muscle Invasive Bladder Cancer (NMIBC), Phase 2 ADVANCED-2 trial, Cell therapy, BCG-Unresponsive, BCG-Naïve

Boston Pharmaceuticals Achieves Phase 2 Success with Efimosfermin Alfa for MASH Treatment, Paving Way for Pivotal Trials

12 months ago talkbio0Tagged Analog, BOS-580, Clinical Trials, efimosfermin alfa, fibroblast growth factor 21, Liver diseases, MASH, metabolic dysfunction-associated steatohepatitis, Nonalcoholic Steatohepatitis, Phase 2, trials

Efimosfermin alfa (BOS-580), Metabolic dysfunction-associated steatohepatitis (MASH), Non-alcoholic steatohepatitis (NASH), Phase 2 clinical trials, FGF21 analogue, Liver disease treatment, Pivotal trials